222 related articles for article (PubMed ID: 28982149)
41. PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation.
Plate JM
Leuk Lymphoma; 2004 Aug; 45(8):1519-29. PubMed ID: 15370202
[TBL] [Abstract][Full Text] [Related]
42. The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2).
Del Valle JM; Engel P; Martín M
J Biol Chem; 2003 May; 278(19):17430-7. PubMed ID: 12621057
[TBL] [Abstract][Full Text] [Related]
43. A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment.
Ferretti E; Bertolotto M; Deaglio S; Tripodo C; Ribatti D; Audrito V; Blengio F; Matis S; Zupo S; Rossi D; Ottonello L; Gaidano G; Malavasi F; Pistoia V; Corcione A
Leukemia; 2011 Aug; 25(8):1268-77. PubMed ID: 21546901
[TBL] [Abstract][Full Text] [Related]
44. The relative expression levels of CD148 and CD180 on clonal B cells and CD148/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow - Results from a single centre pilot study.
Gautam A; Sreedharanunni S; Sachdeva MUS; Rana S; Kashyap D; Bose P; Bal A; Prakash G; Malhotra P; Das R; Varma N
Int J Lab Hematol; 2021 Oct; 43(5):1123-1131. PubMed ID: 33455071
[TBL] [Abstract][Full Text] [Related]
45. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
Redondo-Muñoz J; Escobar-Díaz E; Hernández Del Cerro M; Pandiella A; Terol MJ; García-Marco JA; García-Pardo A
Clin Cancer Res; 2010 Sep; 16(17):4382-91. PubMed ID: 20534739
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen.
Bailón E; Ugarte-Berzal E; Amigo-Jiménez I; Van den Steen P; Opdenakker G; García-Marco JA; García-Pardo A
J Leukoc Biol; 2014 Aug; 96(2):185-99. PubMed ID: 25080557
[TBL] [Abstract][Full Text] [Related]
47. Empirical Study on Exploring the Role of CD180 and MD-1 Prognostic Indicators for the Chronic Lymphocytic Leukaemia (CLL) Disease.
Alotaibi MA
Pak J Biol Sci; 2023 May; 26(6):311-320. PubMed ID: 37902045
[TBL] [Abstract][Full Text] [Related]
48. Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4).
Romero X; Benítez D; March S; Vilella R; Miralpeix M; Engel P
Tissue Antigens; 2004 Aug; 64(2):132-44. PubMed ID: 15245368
[TBL] [Abstract][Full Text] [Related]
49. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.
Cuní S; Pérez-Aciego P; Pérez-Chacón G; Vargas JA; Sánchez A; Martín-Saavedra FM; Ballester S; García-Marco J; Jordá J; Durántez A
Leukemia; 2004 Aug; 18(8):1391-400. PubMed ID: 15175625
[TBL] [Abstract][Full Text] [Related]
50. Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells.
Laytragoon-Lewin N; Duhony E; Bai XF; Mellstedt H
Eur J Haematol; 1998 Oct; 61(4):266-71. PubMed ID: 9820634
[TBL] [Abstract][Full Text] [Related]
51. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).
Uhrmacher S; Schmidt C; Erdfelder F; Poll-Wolbeck SJ; Gehrke I; Hallek M; Kreuzer KA
Leuk Res; 2011 Oct; 35(10):1360-6. PubMed ID: 21531460
[TBL] [Abstract][Full Text] [Related]
52. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules.
Kay NE; Bone ND; Tschumper RC; Howell KH; Geyer SM; Dewald GW; Hanson CA; Jelinek DF
Leukemia; 2002 May; 16(5):911-9. PubMed ID: 11986954
[TBL] [Abstract][Full Text] [Related]
53. HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
Frezzato F; Raggi F; Martini V; Severin F; Trimarco V; Visentin A; Scomazzon E; Accordi B; Bresolin S; Piazza F; Facco M; Basso G; Semenzato G; Trentin L
Int J Cancer; 2019 Dec; 145(11):3089-3100. PubMed ID: 31044428
[TBL] [Abstract][Full Text] [Related]
54. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
Giannoni P; Cutrona G; Totero D
Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
[TBL] [Abstract][Full Text] [Related]
55. BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells.
Talbot H; Saada S; Barthout E; Gallet PF; Gachard N; Abraham J; Jaccard A; Troutaud D; Lalloué F; Naves T; Fauchais AL; Jauberteau MO
Sci Rep; 2020 Jul; 10(1):12572. PubMed ID: 32724091
[TBL] [Abstract][Full Text] [Related]
56. Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
Shukla A; Shukla V; Joshi SS
Leuk Lymphoma; 2018 Jul; 59(7):1565-1573. PubMed ID: 28882083
[TBL] [Abstract][Full Text] [Related]
57. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.
Liu TM; Ling Y; Woyach JA; Beckwith K; Yeh YY; Hertlein E; Zhang X; Lehman A; Awan F; Jones JA; Andritsos LA; Maddocks K; MacMurray J; Salunke SB; Chen CS; Phelps MA; Byrd JC; Johnson AJ
Blood; 2015 Jan; 125(2):284-95. PubMed ID: 25293770
[TBL] [Abstract][Full Text] [Related]
58. Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.
Benkisser-Petersen M; Buchner M; Dörffel A; Dühren-von-Minden M; Claus R; Kläsener K; Leberecht K; Burger M; Dierks C; Jumaa H; Malavasi F; Reth M; Veelken H; Duyster J; Zirlik K
PLoS One; 2016; 11(12):e0169159. PubMed ID: 28036404
[TBL] [Abstract][Full Text] [Related]
59. The role of CD180 in hematological malignancies and inflammatory disorders.
Edwards K; Lydyard PM; Kulikova N; Tsertsvadze T; Volpi EV; Chiorazzi N; Porakishvili N
Mol Med; 2023 Jul; 29(1):97. PubMed ID: 37460961
[TBL] [Abstract][Full Text] [Related]
60. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.
Bologna C; Buonincontri R; Serra S; Vaisitti T; Audrito V; Brusa D; Pagnani A; Coscia M; D'Arena G; Mereu E; Piva R; Furman RR; Rossi D; Gaidano G; Terhorst C; Deaglio S
J Clin Invest; 2016 Jan; 126(1):181-94. PubMed ID: 26619119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
